Skip to main content
Figure 2 | BMC Pediatrics

Figure 2

From: A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

Figure 2

Antimotavizumab and antipalivizumab antibodies detected during the study. Antimotavizumab titers ranged from 1:40 to 1:1250 in the mixed motavizumab/palivizumab treatment group and from 1:10 to 1:250 in the mixed palivizumab/motavizumab treatment group. Final antibody assessments at days 270 to 300 correspond to 120-150 days after the final dose.

Back to article page